Unverricht-Lundborg Disease

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Bruce Ren	+ 578 word(s)	578	2020-12-15 07:40:43

This entry is adapted from the peer-reviewed paper https://medlineplus.gov/genetics/condition/unverricht-lundborg-disease

Unverricht-Lundborg disease is a rare inherited form of epilepsy.

genetic conditions

1. Introduction

Unverricht-Lundborg disease is a rare inherited form of epilepsy. Affected individuals usually begin showing signs and symptoms of the disorder between the ages of 6 and 15.

Unverricht-Lundborg disease is classified as a type of progressive myoclonus epilepsy. People with this disorder experience episodes of involuntary muscle jerking or twitching (myoclonus) that increase in frequency and severity over time. Episodes of myoclonus may be brought on by physical exertion, stress, light, or other stimuli. Within 5 to 10 years, the myoclonic episodes may become severe enough to interfere with walking and other everyday activities.

Affected individuals also usually have seizures involving loss of consciousness, muscle rigidity, and convulsions (tonic-clonic or grand mal seizures). Like the myoclonic episodes, these may increase in frequency over several years but may be controlled with treatment. After several years of progression, the frequency of seizures may stabilize or decrease.

Eventually people with Unverricht-Lundborg disease may develop problems with balance and coordination (ataxia), involuntary rhythmic shaking called intention tremor because it worsens during movement, difficulty speaking (dysarthria), depression, and a slow, mild decline in intellectual functioning.

People with Unverricht-Lundborg disease typically live into adulthood. Depending on the severity of the condition and a person's response to treatment, life expectancy may be normal.

2. Frequency

Progressive myoclonus epilepsy is a rare condition. Unverricht-Lundborg disease is believed to be the most common cause of this type of epilepsy, but its worldwide prevalence is unknown. Unverricht-Lundborg disease occurs most frequently in Finland, where approximately 4 in 100,000 people are affected.

3. Causes

Mutations in the CSTB gene cause Unverricht-Lundborg disease. The CSTB gene provides instructions for making a protein called cystatin B. This protein reduces the activity of enzymes called cathepsins. Cathepsins help break down certain proteins in the lysosomes (compartments in the cell that digest and recycle materials). While the specific function of cystatin B is unclear, it may help protect the cells' proteins from cathepsins that leak out of the lysosomes.

In almost all affected individuals, Unverricht-Lundborg disease is caused by an increase in size of the CSTB gene. One region of the CSTB gene has a particular repeating sequence of 12 DNA building blocks (nucleotides). This sequence is normally repeated two or three times within the gene and is called a dodecamer repeat. Most people with this disorder have more than 30 repeats of the dodecamer sequence in both copies of the CSTB gene. A small number of people with Unverricht-Lundborg disease carry other mutations.

The increased number of dodecamer repeats in the CSTB gene seems to interfere with the production of the cystatin B protein. Levels of cystatin B in affected individuals are only 5 to 10 percent of normal, and cathepsin levels are significantly increased. These changes are believed to cause the signs and symptoms of Unverricht-Lundborg disease, but it is unclear how a reduction in the amount of cystatin B leads to the features of this disorder.

4. Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

5. Other Names for This Condition

Baltic myoclonic epilepsy
Baltic myoclonus
Baltic myoclonus epilepsy
EPM1
Lundborg-Unverricht syndrome
Mediterranean myoclonic epilepsy
myoclonic epilepsy of Unverricht and Lundborg
PME
progressive myoclonic epilepsy
progressive myoclonus epilepsy 1
ULD
Unverricht-Lundborg syndrome

References

Alakurtti K, Virtaneva K, Joensuu T, Palvimo JJ, Lehesjoki AE.Characterization of the cystatin B gene promoter harboring the dodecamer repeatexpanded in progressive myoclonus epilepsy, EPM1. Gene. 2000 Jan25;242(1-2):65-73.
Alakurtti K, Weber E, Rinne R, Theil G, de Haan GJ, Lindhout D, Salmikangas P,Saukko P, Lahtinen U, Lehesjoki AE. Loss of lysosomal association of cystatin Bproteins representing progressive myoclonus epilepsy, EPM1, mutations. Eur J Hum Genet. 2005 Feb;13(2):208-15. Erratum in: Eur J Hum Genet. 2005 Feb;13(2):264.
Ceru S, Rabzelj S, Kopitar-Jerala N, Turk V, Zerovnik E. Protein aggregationas a possible cause for pathology in a subset of familial Unverricht-Lundborgdisease. Med Hypotheses. 2005;64(5):955-9.
Houseweart MK, Pennacchio LA, Vilaythong A, Peters C, Noebels JL, Myers RM.Cathepsin B but not cathepsins L or S contributes to the pathogenesis ofUnverricht-Lundborg progressive myoclonus epilepsy (EPM1). J Neurobiol. 2003 Sep 15;56(4):315-27.
Joensuu T, Kuronen M, Alakurtti K, Tegelberg S, Hakala P, Aalto A, Huopaniemi L, Aula N, Michellucci R, Eriksson K, Lehesjoki AE. Cystatin B: mutationdetection, alternative splicing and expression in progressive myclonus epilepsyof Unverricht-Lundborg type (EPM1) patients. Eur J Hum Genet. 2007Feb;15(2):185-93.
Lalioti MD, Antonarakis SE, Scott HS. The epilepsy, the protease inhibitor andthe dodecamer: progressive myoclonus epilepsy, cystatin b and a 12-mer repeatexpansion. Cytogenet Genome Res. 2003;100(1-4):213-23. Review.
Lehesjoki AE. Molecular background of progressive myoclonus epilepsy. EMBO J. 2003 Jul 15;22(14):3473-8. Review.
Magaudda A, Ferlazzo E, Nguyen VH, Genton P. Unverricht-Lundborg disease, acondition with self-limited progression: long-term follow-up of 20 patients.Epilepsia. 2006 May;47(5):860-6.
Moulard B, Darcel F, Mignard D, Jeanpierre M, Genton P, Cartault F, Yaouanq J,Roubertie A, Biraben A, Buresi C, Malafosse A. FOunder effect in patients withUnverricht-Lundborg disease on reunion island. Epilepsia. 2003Oct;44(10):1357-60.
Moulard B, Genton P, Grid D, Jeanpierre M, Ouazzani R, Mrabet A, Morris M,LeGuern E, Dravet C, Mauguière F, Utermann B, Baldy-Moulinier M, Belaidi H,Bertran F, Biraben A, Ali Chérif A, Chkili T, Crespel A, Darcel F, Dulac O, Geny C, Humbert-Claude V, Kassiotis P, Buresi C, Malafosse A. Haplotype study of West European and North African Unverricht-Lundborg chromosomes: evidence for a fewfounder mutations. Hum Genet. 2002 Sep;111(3):255-62.
Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review ofgenetic and therapeutic aspects. Lancet Neurol. 2005 Apr;4(4):239-48. Review.

©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Genetics & Heredity

Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Bruce Ren

View Times: 495

Entry Collection: MedlinePlus

Update Date: 23 Dec 2020

Table of Contents

Video Upload Options

Confirm

1. Introduction

2. Frequency

3. Causes

4. Inheritance

5. Other Names for This Condition

References

Video Upload Options

Confirm

1. Introduction

2. Frequency

3. Causes

3.1 The gene associated with Unverricht-Lundborg disease

4. Inheritance

5. Other Names for This Condition

References